Annual report
2385.TEDINET S100Z3JY
Period2025-07-01 → 2026-06-30
Filed2026-09-24
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 144
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.9bn | 2025-07-01 → 2026-06-30 | Cons. | Net sales |
| Revenue | ¥4.8bn | 2024-07-01 → 2025-06-30 | Cons. | Net sales |
| Revenue | ¥5.2bn | 2023-07-01 → 2024-06-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.1bn | 2022-07-01 → 2023-06-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥9.3bn | 2021-07-01 → 2022-06-30v | Cons. | Net sales (5-year summary) |
| Operating income | ¥276m | 2025-07-01 → 2026-06-30 | Cons. | Operating income |
| Operating income | −¥138m | 2024-07-01 → 2025-06-30 | Cons. | Operating income |
| Ordinary income | ¥288m | 2025-07-01 → 2026-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥129m | 2024-07-01 → 2025-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥566m | 2023-07-01 → 2024-06-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥727m | 2022-07-01 → 2023-06-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2021-07-01 → 2022-06-30v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥230m | 2025-07-01 → 2026-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥220m | 2024-07-01 → 2025-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥212m | 2025-07-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥211m | 2024-07-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥662m | 2023-07-01 → 2024-06-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥452m | 2022-07-01 → 2023-06-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥810m | 2021-07-01 → 2022-06-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥212m | 2025-07-01 → 2026-06-30 | Cons. | Profit loss |
| Net income | −¥211m | 2024-07-01 → 2025-06-30 | Cons. | Profit loss |
| Total assets | ¥6.9bn | at 2026-06-30 | Cons. | Assets |
| Total assets | ¥6.8bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥6.9bn | at 2024-06-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.2bn | at 2023-06-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.5bn | at 2022-06-30v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥742m | at 2026-06-30 | Cons. | Liabilities |
| Total liabilities | ¥775m | at 2025-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥6.1bn | at 2026-06-30 | Cons. | Net assets |
| Net assets / equity | ¥6.0bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥6.2bn | at 2024-06-30v | Cons. | Net assets |
| Net assets / equity | ¥7.2bn | at 2023-06-30v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥6.8bn | at 2022-06-30v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.4bn | at 2026-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.0bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.4bn | at 2026-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.0bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.8bn | at 2024-06-30v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.9bn | at 2023-06-30v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥6.0bn | at 2022-06-30v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥415m | 2025-07-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥558m | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥881m | 2023-07-01 → 2024-06-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥102m | 2022-07-01 → 2023-06-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.1bn | 2021-07-01 → 2022-06-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥119m | 2025-07-01 → 2026-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥389m | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥14m | 2023-07-01 → 2024-06-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥160m | 2022-07-01 → 2023-06-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥245m | 2021-07-01 → 2022-06-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥140m | 2025-07-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥214,000 | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥261m | 2023-07-01 → 2024-06-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥130m | 2022-07-01 → 2023-06-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥130m | 2021-07-01 → 2022-06-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥8.12 | 2025-07-01 → 2026-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.05 | 2024-07-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-25.32 | 2023-07-01 → 2024-06-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.27 | 2022-07-01 → 2023-06-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.95 | 2021-07-01 → 2022-06-30v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥233.56 | at 2026-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥230.22 | at 2025-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥238.28 | at 2024-06-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥266.41 | at 2023-06-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥254.14 | at 2022-06-30v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 89.2% | at 2026-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.4% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.7% | at 2024-06-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.6% | at 2023-06-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.3% | at 2022-06-30v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 3.5% | 2025-07-01 → 2026-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2022-07-01 → 2023-06-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.8% | 2021-07-01 → 2022-06-30v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 45 | at 2026-06-30 | Cons. | Number of employees |
| Employees | 81 | at 2025-06-30 | Cons. | Number of employees |
| Employees | 90 | at 2024-06-30v | Cons. | Number of employees |
| Employees | 98 | at 2023-06-30v | Cons. | Number of employees |
| Employees | 100 | at 2022-06-30v | Cons. | Number of employees |
| Revenue | ¥838m | 2025-07-01 → 2026-06-30 | Standalone | Net sales |
| Revenue | ¥753m | 2024-07-01 → 2025-06-30 | Standalone | Net sales |
| Revenue | ¥304m | 2023-07-01 → 2024-06-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥377m | 2022-07-01 → 2023-06-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥439m | 2021-07-01 → 2022-06-30v | Standalone | Net sales (5-year summary) |
| Operating income | ¥528m | 2025-07-01 → 2026-06-30 | Standalone | Operating income |
| Operating income | ¥409m | 2024-07-01 → 2025-06-30 | Standalone | Operating income |
| Ordinary income | ¥538m | 2025-07-01 → 2026-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥420m | 2024-07-01 → 2025-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥2m | 2023-07-01 → 2024-06-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥87m | 2022-07-01 → 2023-06-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥137m | 2021-07-01 → 2022-06-30v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥262m | 2025-07-01 → 2026-06-30 | Standalone | Income before income taxes |
| Profit before tax | ¥388m | 2024-07-01 → 2025-06-30 | Standalone | Income before income taxes |
| Net income | ¥334m | 2025-07-01 → 2026-06-30 | Standalone | Profit loss |
| Net income | ¥448m | 2024-07-01 → 2025-06-30 | Standalone | Profit loss |
| Net income | −¥10m | 2023-07-01 → 2024-06-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥142m | 2022-07-01 → 2023-06-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥195m | 2021-07-01 → 2022-06-30v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥4.9bn | at 2026-06-30 | Standalone | Assets |
| Total assets | ¥4.7bn | at 2025-06-30 | Standalone | Assets |
| Total assets | ¥4.2bn | at 2024-06-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.3bn | at 2023-06-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.5bn | at 2022-06-30v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥62m | at 2026-06-30 | Standalone | Liabilities |
| Total liabilities | ¥59m | at 2025-06-30 | Standalone | Liabilities |
| Net assets / equity | ¥4.8bn | at 2026-06-30 | Standalone | Net assets |
| Net assets / equity | ¥4.6bn | at 2025-06-30 | Standalone | Net assets |
| Net assets / equity | ¥4.1bn | at 2024-06-30v | Standalone | Net assets |
| Net assets / equity | ¥4.3bn | at 2023-06-30v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.3bn | at 2022-06-30v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.8bn | at 2026-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.4bn | at 2025-06-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥12.76 | 2025-07-01 → 2026-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.11 | 2024-07-01 → 2025-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-0.4 | 2023-07-01 → 2024-06-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.44 | 2022-07-01 → 2023-06-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥7.47 | 2021-07-01 → 2022-06-30v | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥10 | 2025-07-01 → 2026-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2024-07-01 → 2025-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2022-07-01 → 2023-06-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2021-07-01 → 2022-06-30v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥183.43 | at 2026-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥175.67 | at 2025-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥158.55 | at 2024-06-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥163.95 | at 2023-06-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥163.52 | at 2022-06-30v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 98.7% | at 2026-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.7% | at 2025-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 99.3% | at 2024-06-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 99.5% | at 2023-06-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.6% | at 2022-06-30v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 7.1% | 2025-07-01 → 2026-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.2% | 2024-07-01 → 2025-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.3% | 2022-07-01 → 2023-06-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.6% | 2021-07-01 → 2022-06-30v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 26,158,200 | at 2026-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 26,158,200 | at 2025-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 26,158,200 | at 2024-06-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 26,158,200 | at 2023-06-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 26,158,200 | at 2022-06-30v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 7 | at 2026-06-30 | Standalone | Number of employees |
| Employees | 9 | at 2025-06-30 | Standalone | Number of employees |
| Employees | 11 | at 2024-06-30v | Standalone | Number of employees |
| Employees | 7 | at 2023-06-30v | Standalone | Number of employees |
| Employees | 9 | at 2022-06-30v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 94
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-07-01 → 2026-06-30 | ¥355,000 |
| Reconciling Itemsreconciling | depreciation | 2025-07-01 → 2026-06-30 | ¥419,000 |
| Reconciling Itemsreconciling | revenue | 2025-07-01 → 2026-06-30 | −¥52m |
| Reconciling Itemsreconciling | revenue external | 2025-07-01 → 2026-06-30 | ¥2m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-07-01 → 2026-06-30 | −¥53m |
| Reconciling Itemsreconciling | segment assets | at 2026-06-30 | ¥3.2bn |
| Reconciling Itemsreconciling | segment profit | 2025-07-01 → 2026-06-30 | −¥309m |
| Clinical Evidence Servicereportable segment | capex | 2025-07-01 → 2026-06-30 | ¥316,000 |
| Clinical Evidence Servicereportable segment | depreciation | 2025-07-01 → 2026-06-30 | ¥112,000 |
| Clinical Evidence Servicereportable segment | employees | at 2026-06-30 | 9 pure |
| Clinical Evidence Servicereportable segment | revenue | 2025-07-01 → 2026-06-30 | ¥215m |
| Clinical Evidence Servicereportable segment | revenue external | 2025-07-01 → 2026-06-30 | ¥215m |
| Clinical Evidence Servicereportable segment | segment assets | at 2026-06-30 | ¥324m |
| Clinical Evidence Servicereportable segment | segment profit | 2025-07-01 → 2026-06-30 | ¥15m |
| Functional Cosmetic Retailingreportable segment | employees | at 2026-06-30 | 1 pure |
| Functional Cosmetic Retailingreportable segment | revenue | 2025-07-01 → 2026-06-30 | ¥907m |
| Functional Cosmetic Retailingreportable segment | revenue external | 2025-07-01 → 2026-06-30 | ¥883m |
| Functional Cosmetic Retailingreportable segment | revenue intersegment | 2025-07-01 → 2026-06-30 | ¥24m |
| Functional Cosmetic Retailingreportable segment | segment assets | at 2026-06-30 | ¥142m |
| Functional Cosmetic Retailingreportable segment | segment profit | 2025-07-01 → 2026-06-30 | ¥48m |
| Functional Food Retailingreportable segment | capex | 2025-07-01 → 2026-06-30 | ¥362,000 |
| Functional Food Retailingreportable segment | depreciation | 2025-07-01 → 2026-06-30 | ¥8m |
| Functional Food Retailingreportable segment | employees | at 2026-06-30 | 13 pure |
| Functional Food Retailingreportable segment | revenue | 2025-07-01 → 2026-06-30 | ¥1.7bn |
| Functional Food Retailingreportable segment | revenue external | 2025-07-01 → 2026-06-30 | ¥1.7bn |
| Functional Food Retailingreportable segment | revenue intersegment | 2025-07-01 → 2026-06-30 | ¥15m |
| Functional Food Retailingreportable segment | segment assets | at 2026-06-30 | ¥2.4bn |
| Functional Food Retailingreportable segment | segment profit | 2025-07-01 → 2026-06-30 | ¥329m |
| Functional Material Developmentreportable segment | depreciation | 2025-07-01 → 2026-06-30 | ¥44,000 |
| Functional Material Developmentreportable segment | employees | at 2026-06-30 | 1 pure |
| Functional Material Developmentreportable segment | revenue | 2025-07-01 → 2026-06-30 | ¥311m |
| Functional Material Developmentreportable segment | revenue external | 2025-07-01 → 2026-06-30 | ¥297m |
| Functional Material Developmentreportable segment | revenue intersegment | 2025-07-01 → 2026-06-30 | ¥14m |
| Functional Material Developmentreportable segment | segment assets | at 2026-06-30 | ¥277m |
| Functional Material Developmentreportable segment | segment profit | 2025-07-01 → 2026-06-30 | ¥33m |
| Health Care Support Servicereportable segment | capex | 2025-07-01 → 2026-06-30 | ¥37m |
| Health Care Support Servicereportable segment | depreciation | 2025-07-01 → 2026-06-30 | ¥4m |
| Health Care Support Servicereportable segment | employees | at 2026-06-30 | 14 pure |
| Health Care Support Servicereportable segment | revenue | 2025-07-01 → 2026-06-30 | ¥787m |
| Health Care Support Servicereportable segment | revenue external | 2025-07-01 → 2026-06-30 | ¥787m |
| Health Care Support Servicereportable segment | segment assets | at 2026-06-30 | ¥451m |
| Health Care Support Servicereportable segment | segment profit | 2025-07-01 → 2026-06-30 | ¥160m |
| —segment total | capex | 2025-07-01 → 2026-06-30 | ¥37m |
| —segment total | depreciation | 2025-07-01 → 2026-06-30 | ¥13m |
| —segment total | revenue | 2025-07-01 → 2026-06-30 | ¥3.9bn |
| —segment total | revenue external | 2025-07-01 → 2026-06-30 | ¥3.9bn |
| —segment total | revenue intersegment | 2025-07-01 → 2026-06-30 | ¥53m |
| —segment total | segment assets | at 2026-06-30 | ¥3.6bn |
| —segment total | segment profit | 2025-07-01 → 2026-06-30 | ¥585m |
| Reconciling Itemsreconciling | capex | 2024-07-01 → 2025-06-30 | ¥548,000 |
| Reconciling Itemsreconciling | depreciation | 2024-07-01 → 2025-06-30 | ¥557,000 |
| Reconciling Itemsreconciling | revenue | 2024-07-01 → 2025-06-30 | −¥26m |
| Reconciling Itemsreconciling | revenue external | 2024-07-01 → 2025-06-30 | ¥2m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-07-01 → 2025-06-30 | −¥28m |
| Reconciling Itemsreconciling | segment assets | at 2025-06-30 | ¥2.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-07-01 → 2025-06-30 | −¥343m |
| Clinical Evidence Servicereportable segment | capex | 2024-07-01 → 2025-06-30 | ¥4m |
| Clinical Evidence Servicereportable segment | depreciation | 2024-07-01 → 2025-06-30 | ¥6m |
| Clinical Evidence Servicereportable segment | revenue | 2024-07-01 → 2025-06-30 | ¥242m |
| Clinical Evidence Servicereportable segment | revenue external | 2024-07-01 → 2025-06-30 | ¥242m |
| Clinical Evidence Servicereportable segment | segment assets | at 2025-06-30 | ¥321m |
| Clinical Evidence Servicereportable segment | segment profit | 2024-07-01 → 2025-06-30 | ¥9m |
| Functional Cosmetic Retailingreportable segment | capex | 2024-07-01 → 2025-06-30 | ¥30m |
| Functional Cosmetic Retailingreportable segment | depreciation | 2024-07-01 → 2025-06-30 | ¥2m |
| Functional Cosmetic Retailingreportable segment | revenue | 2024-07-01 → 2025-06-30 | ¥1.5bn |
| Functional Cosmetic Retailingreportable segment | revenue external | 2024-07-01 → 2025-06-30 | ¥1.5bn |
| Functional Cosmetic Retailingreportable segment | segment assets | at 2025-06-30 | ¥745m |
| Functional Cosmetic Retailingreportable segment | segment profit | 2024-07-01 → 2025-06-30 | ¥27m |
| Functional Food Retailingreportable segment | capex | 2024-07-01 → 2025-06-30 | ¥357,000 |
| Functional Food Retailingreportable segment | depreciation | 2024-07-01 → 2025-06-30 | ¥8m |
| Functional Food Retailingreportable segment | revenue | 2024-07-01 → 2025-06-30 | ¥2.1bn |
| Functional Food Retailingreportable segment | revenue external | 2024-07-01 → 2025-06-30 | ¥2.1bn |
| Functional Food Retailingreportable segment | revenue intersegment | 2024-07-01 → 2025-06-30 | ¥13m |
| Functional Food Retailingreportable segment | segment assets | at 2025-06-30 | ¥1.1bn |
| Functional Food Retailingreportable segment | segment profit | 2024-07-01 → 2025-06-30 | ¥91m |
| Functional Material Developmentreportable segment | depreciation | 2024-07-01 → 2025-06-30 | ¥297,000 |
| Functional Material Developmentreportable segment | revenue | 2024-07-01 → 2025-06-30 | ¥298m |
| Functional Material Developmentreportable segment | revenue external | 2024-07-01 → 2025-06-30 | ¥283m |
| Functional Material Developmentreportable segment | revenue intersegment | 2024-07-01 → 2025-06-30 | ¥15m |
| Functional Material Developmentreportable segment | segment assets | at 2025-06-30 | ¥1.3bn |
| Functional Material Developmentreportable segment | segment profit | 2024-07-01 → 2025-06-30 | −¥28m |
| Health Care Support Servicereportable segment | capex | 2024-07-01 → 2025-06-30 | ¥3m |
| Health Care Support Servicereportable segment | depreciation | 2024-07-01 → 2025-06-30 | ¥1m |
| Health Care Support Servicereportable segment | revenue | 2024-07-01 → 2025-06-30 | ¥688m |
| Health Care Support Servicereportable segment | revenue external | 2024-07-01 → 2025-06-30 | ¥688m |
| Health Care Support Servicereportable segment | segment assets | at 2025-06-30 | ¥528m |
| Health Care Support Servicereportable segment | segment profit | 2024-07-01 → 2025-06-30 | ¥107m |
| —segment total | capex | 2024-07-01 → 2025-06-30 | ¥37m |
| —segment total | depreciation | 2024-07-01 → 2025-06-30 | ¥18m |
| —segment total | revenue | 2024-07-01 → 2025-06-30 | ¥4.9bn |
| —segment total | revenue external | 2024-07-01 → 2025-06-30 | ¥4.8bn |
| —segment total | revenue intersegment | 2024-07-01 → 2025-06-30 | ¥28m |
| —segment total | segment assets | at 2025-06-30 | ¥4.0bn |
| —segment total | segment profit | 2024-07-01 → 2025-06-30 | ¥205m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,295
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 0 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 0 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 0.759 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.691 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.399 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.412 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.533 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 0.548 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 0.676 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 0.548 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 0.620 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 0.585 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | － | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 50 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | － | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 100 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 100 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 100 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | － | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | 100 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row5Member | 65.0 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row5Member | 85 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row6Member | 98.7 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row6Member | 90 | |
| Research and development expenses research and development activities | CurrentYearDuration | 29000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 16000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 3000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 5000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 3000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 37765000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05367-000HealthCareSupportServiceReportableSegmentsMember | 36731000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 26158200 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 26158200 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 26158200 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 26158200 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 1 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 21 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 72 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 26 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 87 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 14234 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 14441 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 27 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 3856 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 3451 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 51894 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 898 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |